title: Chronic neonatal blockade of N-methyl-D-aspartate receptor by CGP 39551 increases dopaminergic function in adult rat.
abstract: Following chronic neonatal treatment with the competitive N-methyl-D-aspartate antagonist CGP 39551, adult rats showed increased behavioral responses to the D2 dopamine receptor stimulation. In nucleus accumbens and in n. striatum of similarly treated rats increases in D2 dopamine receptor number were observed. CGP 39551 was administered daily to neonatal rats with increasing doses from postnatal day 1 to 22. At postnatal days 70-82, the rats were observed for hyperactivity induced by the selective D2 dopamine receptor agonist LY 171555, the grooming behavior elicited by the specific D1 dopamine receptor stimulating agent SKF 38393 and the stereotypies induced by the mixed D1/D2 receptor agonist apomorphine. [3H]Spiroperidol and [3H]SCH 23390 specific binding to membranes of nucleus accumbens, nucleus striatum and frontal cortex of similarly treated rats was measured. The hypermotility and the stereotyped behavior induced by LY 171555 and apomorphine, respectively, were augmented, whereas grooming behavior elicited by SKF 38393 was unaffected, in CGP 39551-treated rats. Consistently, both in nucleus accumbens and in n. striatum an increase in [3H]Spiroperidol specific binding was observed, while [3H]SCH 23390 specific binding did not change. The study demonstrates that chronic blockade of N-methyl-D-aspartate receptor during the critical period of brain maturation results in long-lasting dopaminergic functional changes.
authors.affiliation: Department of Pharmacology, University of Bologna, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Dall'Olio
authors.forename: F
authors.initials: F
authors.lastname: Facchinetti
authors.forename: A
authors.initials: A
authors.lastname: Contestabile
authors.forename: O
authors.initials: O
authors.lastname: Gandolfi
mesh_terms: D015763:2-Amino-5-phosphonovalerate / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D000831:Animals, Newborn; D001058:Apomorphine / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000502:physiology*; D018491:Dopamine Agonists / Q000494:pharmacology; D004873:Ergolines / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D019257:Quinpirole; D051381:Rats; D017208:Rats, Wistar; D011954:Receptors, Dopamine / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D013134:Spiperone / Q000378:metabolism; D013239:Stereotyped Behavior / Q000187:drug effects; D013997:Time Factors
chemical_list: D018491:Dopamine Agonists; D004873:Ergolines; D011954:Receptors, Dopamine; D016194:Receptors, N-Methyl-D-Aspartate; C064540:CGP 39551; D019257:Quinpirole; D013134:Spiperone; D015763:2-Amino-5-phosphonovalerate; D001058:Apomorphine; D004298:Dopamine